BAX vs FMS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BAX and FMS are similarly sized, but FMS trades noticeably cheaper on forward earnings (8.50x vs 12.60x): the market is paying up for BAX's profile and pricing FMS more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
BAX vs FMS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BAX | FMS | What it tells you |
|---|---|---|---|
| Market cap | $13.33B | $11.82B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 12.60 | 8.50 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.67 | 0.79 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 70% of range | 43% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.05 | 0.82 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: FMS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BAX and FMS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and FMS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and FMS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Baxter International (BAX) do?
Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.
What does Fresenius Medical Care (FMS) do?
Fresenius Medical Care treats end-stage kidney disease, the point at which a patient's kidneys have failed and dialysis or a transplant is the only option. It runs the largest network of outpatient dialysis clinics in the world, with the large majority of revenue coming from the United States, and it also manufactures the machines, dialyzers, bloodlines and water-treatment systems those clinics use, selling that equipment to third parties including its own competitors. Since a 2023 reorganisation the company reports in two segments: Care Delivery, the clinic network, and Care Enablement, the products business. Demand is close to non-discretionary, since a patient on hemodialysis typically needs three sessions a week indefinitely, but the price of each session in the US is set largely by Medicare rather than negotiated.
BAX vs FMS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
- FMS drivers: The FME25+ cost program, and what comes after it; US reimbursement and the TDAPA roll-off.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For FMS, the long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years.
BAX or FMS: which should you pick?
BAX vs FMS: the full fundamentals
BAX. Baxter trades at about 12.6 times forward earnings and roughly 1.2 times sales, a modest valuation for medtech that reflects its low-growth profile and the debt load, even after a 31% rally in 2026. Reported GAAP profit is still negative over the trailing year because of special charges, so adjusted metrics and the coming October 29 report (consensus about $0.52 per share) carry most of the weight.
FMS. A sub-one-times-sales multiple and a trailing P/E near 11 are unusual for a healthcare services business with near non-discretionary demand, and they price in the flat volumes and reimbursement ceiling rather than any doubt about the need for the service. Because the company reports in euros and earns most of its revenue in dollars, screeners that convert figures at a spot rate will not match the company's own release. Analysts are cautious (seven cover the ADS with a Hold consensus and a mean target near $24), and the November 3 report will be the first under the new CEO.
Headline figures (approximate, October 2026): BAX shows revenue (ttm) ~$11.5B, q2 2026 sales ~$2.96B, up ~5% year over year, q2 2026 adjusted eps ~$0.56 vs ~$0.37 expected, operating margin (ttm) ~14%; FMS shows revenue (ttm) ~$19.4B (reported in euros; Q2 2026 ~+4% at constant currency), operating margin (ttm) ~11% (Q2 2026 ex special items ~11.7%), net income (ttm) ~$0.94B, p/e (trailing / forward) ~11x / ~7x.
The bottom line: BAX vs FMS
BAX and FMS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and FMS exposure against your real portfolio. It is not an investment adviser.
Wondering how BAX or FMS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Baxter International
Ask Walnut's AI anything about BAX and see how it fits what you own.
FAQ
What is the difference between BAX and FMS?
+
Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. Fresenius Medical Care treats end-stage kidney disease, the point at which a patient's kidneys have failed and dialysis or a transplant is the only option. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BAX or FMS the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BAX or FMS?
+
On forward P/E (as of November 2026), BAX trades at 12.60x and FMS at 8.50x, so FMS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BAX and FMS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BAX vs FMS?
+
BAX: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $9.7 billion in total as of June 2026) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure, and the company still shows a GAAP net loss of roughly $968 million over the trailing twelve months. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. After a 31% rally, expectations are higher going into the third quarter, Wall Street's average rating is hold, and the average target of about $27.92 sits only modestly above the share price. The turnaround is early and could take longer than management projects. FMS: The long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years. Legal and regulatory exposure is real and ongoing: the Department of Justice has intervened in a False Claims Act case alleging medically unnecessary vascular procedures at a Fresenius subsidiary, the 2024 recall of 2008 series hemodialysis machines over compounds leaching from silicone tubing has drawn product-liability attention, and in September 2026 the FDA issued a warning about leaking dialysis bags. A leadership change brings its own execution risk, and the China exit adds about EUR 110 million of one-time costs to the third quarter, when consensus already expects EPS to fall year over year. Because the company reports in euros while earning most of its revenue in dollars, headline growth can diverge sharply from constant-currency growth. US clinic labour costs and nurse availability remain a persistent margin pressure, and debt of about $11 billion is meaningful for a business with this little top-line growth. As a German issuer, dividends are subject to German withholding tax before they reach a US ADS holder, and the company files as a foreign private issuer rather than on the domestic quarterly schedule.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BAX or FMS; figures are approximate and dated (as of November 2026). Verify current data before investing.